Literature DB >> 14870991

Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances.

Alice B Gottlieb1.   

Abstract

Immunobiologics provide the hope for safe and effective long-term management of psoriasis, a life-disabling condition. The use of targeted immunotherapies as pathogenic probes has led to scientific discoveries that help uncover new information on the pathogenesis of psoriasis and on the control of cutaneous immunity. The research described in this paper employs targeted immunotherapies as pathogenic probes of T1-mediated immune disorders, using psoriasis as the primary disease model. This approach has wide applicability to other immune-mediated inflammatory isorders.

Entities:  

Mesh:

Year:  2004        PMID: 14870991     DOI: 10.1111/j.1087-0024.2004.00831.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  3 in total

1.  Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.

Authors:  Peter Wolf; Dat X Nghiem; Jeffrey P Walterscheid; Scott Byrne; Yumi Matsumura; Yasuhiro Matsumura; Cora Bucana; Honnavara N Ananthaswamy; Stephen E Ullrich
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

2.  Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.

Authors:  Vibeke Strand; M Elaine Husni; Keith A Betts; Yan Song; Rakesh Singh; Jenny Griffith; Marci Beppu; Jing Zhao; Arijit Ganguli
Journal:  BMC Rheumatol       Date:  2018-02-12

3.  Treatment Effects upon Prolactin and Soluble Receptor of Interleukin-2 in Psoriatic Patients.

Authors:  Delia Botezatu; Mihaela Tovaru; Simona-Roxana Georgescu; Antoanela Curici; Calin Giurcaneanu
Journal:  Maedica (Bucur)       Date:  2018-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.